TherApeutics in Early ProState Cancer (TAPS02)

This is a phase 2, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.

Trial Details

NCT ID
NCT05191680
Phase
PHASE2
Sponsor
Cambridge University Hospitals NHS Foundation Trust
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Apalutamide Oral Tablet [Erleada]
  • Placebo
Locations (sample)
  • Cambridge, Cambridgeshire, United Kingdom|52.2,0.11667
  • Bristol, United Kingdom|51.45523,-2.59665
  • Bury St Edmunds, United Kingdom|52.2463,0.71111
  • Dartford, United Kingdom|51.44657,0.21423
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • To be included in the trial the patient must:
  • Have given written informed consent to participate.
  • Be aged 18 or over.
  • Have an Eastern Cooperative Oncology Group (ECOG) status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →